Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 433Carcinoma, Non-Small-Cell Lung 372Neoplasms 326Prostatic Neoplasms 244Leukemia, Myeloid, Acute 231Multiple Myeloma 230Neoplasm Metastasis 215Melanoma 202Lung Neoplasms 178Leukemia 172Lymphoma 170Colorectal Neoplasms 157Pancreatic Neoplasms 151Lymphoma, Non-Hodgkin 150Recurrence 149Ovarian Neoplasms 146Leukemia, Lymphocytic, Chronic, B-Cell 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 131Myelodysplastic Syndromes 121Carcinoma, Renal Cell 121Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Follicular 108Brain Neoplasms 101Squamous Cell Carcinoma of Head and Neck 96Head and Neck Neoplasms 96Glioblastoma 92Urinary Bladder Neoplasms 88Carcinoma, Hepatocellular 80Hodgkin Disease 73Colonic Neoplasms 73

Interventions

osimertinib 1aumolertinib 1Taxes 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Clinical Trials, Phase I as Topic 1Cisplatin 1Carboplatin 1BID protein, human 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × NSCLC × Clear all
NCT04820023 2025-06-06

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Bridge Biotherapeutics, Inc.

Phase 1/2 Terminated
45 enrolled 19 charts
Thoracic

NSCLC

NCT04402008 2024-06-25

Study of Poziotinib in Japanese Patients With NSCLC

Spectrum Pharmaceuticals, Inc

Phase 1/2 Terminated
42 enrolled 16 charts
Thoracic

NSCLC

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡